The FY21 ASADRP Consortium Award will support the establishment of a Consortium whose purpose is to conduct multidisciplinary, team-based translational research efforts to identify promising compounds and conduct preclinical and clinical research to test potential medications or medication combinations in humans with ASUD and comorbid PTSD and other psychological disorders, and to explore precision medicine tools for matching patients to these medications. The goal of this research is to reduce the burden of ASUD in society, to include reducing the overall number of opioid-related overdose deaths.
The Consortium will build on the research previously supported by two ASADRP consortia: Institute for Translational Neuroscience and Pharmacotherapies for Alcohol and Substance Abuse. Information about the ASADRP can be found at https://cdmrp.army.mil/asadrp/default.
The Consortium will ultimately consist of a single management core as well as basic research and clinical trial sites. The Consortium participants will be jointly responsible for prioritizing, proposing, conducting, and analyzing basic research and clinical trials and developing a roadmap to translate basic science knowledge into enhanced clinical pharmacological treatment protocols for ASUD.
Deadlines:
• Required Pre-Application Submission Deadline: Aug. 18, 2021
• Application Submission Deadline: Sep. 8, 2021
The Consortium will align its research studies to address all the following Focus Areas:
Independent intramural (DOD) and extramural investigators at all academic levels (or equivalent) are eligible to submit applications. Eligible investigators must apply through an organization.
An investigator may be named as a CMC PI on only one FY21 ASADRP Consortium Award application.
The anticipated total costs budgeted for the entire period of performance for an FY21 ASADRP Consortium Award will not exceed $10.575M, of which only $3.525M is currently available. The ASADRP Consortium Award will be funded initially with allocations from the FY21 ASADRP congressional appropriation ($3.525M). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
